 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C18H19NO |
| Molar mass | 265.356 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
HP-505 is a triple reuptake inhibitor that was investigated by Hoechst-Roussel Pharmaceuticals. [1] In mice, HP-505 was a potent inhibitor of tetrabenazine-induced ptosis which may indicate antidepressant activity. [2]
Pharmacology
| 5-HT | NE | DA | NE:5-HT | DA:5-HT |
|---|---|---|---|---|
| 0.19 ± 0.04 | 0.34 ± 0.1 | 0.66 ± 0.15 | 1.8 | 3.5 |
The inhibitory effect of HP-505 on serotonin reuptake is approximately 1.8 and 3.5 times stronger than on norepinephrine and dopamine, respectively. [1] Subsequent investigations have found that HP-505 acts on presynaptic dopamine transporters and is devoid of anticholinergic effects. [3]
Synthesis
The N-methylated analog is called HP-365 [59142-29-9].
An older synthesis is available, although more modern methods exist now: [4]
References
- ^ a b c Meyerson LR, Ong HH, Martin LL, Ellis DB (June 1980). "Effect of antidepressant agents on beta-adrenergic receptor and neurotransmitter regulatory systems". Pharmacology, Biochemistry, and Behavior. 12 (6): 943–948. doi: 10.1016/0091-3057(80)90457-8. PMID 6105676. S2CID 45400599.
- ^ Klioze SS, Bauer VJ, Geyer HM (April 1977). "Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 2. Compounds containing a heteroatom attached to nitrogen". Journal of Medicinal Chemistry. 20 (4): 610–612. doi: 10.1021/jm00214a039. PMID 850252.
- ^ Puri SK, Mantione CR, Petko W, Ellis DB (1979). "Spiroisobenzofuran Piperidine Derivatives. Interaction with Pre- and Post-Synaptic Dopaminergic Sites". In Usdin E, Kopin IJ, Barchas J (eds.). Catecholamines: Basic and Clinical Frontiers. Pergamon. pp. 514–516. doi: 10.1016/B978-1-4832-8363-0.50158-0. ISBN 978-1-4832-8363-0.
- ^ Maier, C. A., Wünsch, B. (1 January 2002). "Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1". Journal of Medicinal Chemistry. 45 (2): 438–448. doi: 10.1021/jm010992z. ISSN 0022-2623.
- ^ Victor J. Bauer & Raymond W. Kosley, Jr., U.S. patent 3,959,475 (1976 to CNA Holdings LLC).
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C18H19NO |
| Molar mass | 265.356 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
HP-505 is a triple reuptake inhibitor that was investigated by Hoechst-Roussel Pharmaceuticals. [1] In mice, HP-505 was a potent inhibitor of tetrabenazine-induced ptosis which may indicate antidepressant activity. [2]
Pharmacology
| 5-HT | NE | DA | NE:5-HT | DA:5-HT |
|---|---|---|---|---|
| 0.19 ± 0.04 | 0.34 ± 0.1 | 0.66 ± 0.15 | 1.8 | 3.5 |
The inhibitory effect of HP-505 on serotonin reuptake is approximately 1.8 and 3.5 times stronger than on norepinephrine and dopamine, respectively. [1] Subsequent investigations have found that HP-505 acts on presynaptic dopamine transporters and is devoid of anticholinergic effects. [3]
Synthesis
The N-methylated analog is called HP-365 [59142-29-9].
An older synthesis is available, although more modern methods exist now: [4]
References
- ^ a b c Meyerson LR, Ong HH, Martin LL, Ellis DB (June 1980). "Effect of antidepressant agents on beta-adrenergic receptor and neurotransmitter regulatory systems". Pharmacology, Biochemistry, and Behavior. 12 (6): 943–948. doi: 10.1016/0091-3057(80)90457-8. PMID 6105676. S2CID 45400599.
- ^ Klioze SS, Bauer VJ, Geyer HM (April 1977). "Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 2. Compounds containing a heteroatom attached to nitrogen". Journal of Medicinal Chemistry. 20 (4): 610–612. doi: 10.1021/jm00214a039. PMID 850252.
- ^ Puri SK, Mantione CR, Petko W, Ellis DB (1979). "Spiroisobenzofuran Piperidine Derivatives. Interaction with Pre- and Post-Synaptic Dopaminergic Sites". In Usdin E, Kopin IJ, Barchas J (eds.). Catecholamines: Basic and Clinical Frontiers. Pergamon. pp. 514–516. doi: 10.1016/B978-1-4832-8363-0.50158-0. ISBN 978-1-4832-8363-0.
- ^ Maier, C. A., Wünsch, B. (1 January 2002). "Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1". Journal of Medicinal Chemistry. 45 (2): 438–448. doi: 10.1021/jm010992z. ISSN 0022-2623.
- ^ Victor J. Bauer & Raymond W. Kosley, Jr., U.S. patent 3,959,475 (1976 to CNA Holdings LLC).
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |